Endo Health Solutions, Inc.
| Nasdaq: ENDP
Endo Health Solutions, Inc. is a U. S. based diversified healthcare company, which redefines healthcare value by finding solutions for the unmet needs of patients along care pathways for pain management, pelvic health, urology, endocrinology and oncology. The company operates through four segments: Endo Pharmaceuticals, Qualitest, AMS and HealthTronics. The Endo Pharmaceuticals segment includes a variety of branded prescription products related to treating and managing pain as well as its urology, endocrinology and oncology products. The marketed products that are included in this segment include Lidoderm, Opana, ER, Percocet, Voltaren Gel, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel. The Qualitest segment focuses on selective generics related to pain that have one or more barriers to market entry, such as complex formulation, regulatory or legal challenges or difficulty in raw material sourcing. It also includes products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health and hypertension markets, among others. The AMS segment currently focuses on providing technology solutions to physicians treating men's and women's pelvic health conditions and operates in the following business lines: men's health, women's health, and BPH therapy. The HealthTronics segment provides urological services, products and support systems to urologists, hospitals, surgery centers and clinics across the U.S. These services are sold through the following business lines: lithotripsy services, prostate treatment services, anatomical pathology services, medical products manufacturing, sales and maintenance and electronic medical records services. Endo Health Solutions was founded by Carol A. Ammon in 1920 and is headquartered in Malvern, PA.